申请人:Epizyme, Inc.
公开号:US10227307B2
公开(公告)日:2019-03-12
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described.
本文描述了式(I)化合物、其药学上可接受的盐及其药物组合物。本文所述化合物可用于抑制 PRMT1 活性。还描述了使用这些化合物治疗 PRMT1 介导的疾病的方法。